Defining the role of endothelial Piezo1, a mechanosensitive ion channel, in providing resilience to vascular contributions to cognitive impairment and dementia (VCID)
定义内皮 Piezo1(一种机械敏感离子通道)在为认知障碍和痴呆 (VCID) 的血管提供恢复能力方面的作用
基本信息
- 批准号:10419669
- 负责人:
- 金额:$ 62.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-15 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AgingAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAmyloid beta-ProteinArteriesBasic ScienceBilateralBiological AssayBlood VesselsBlood flowBrainBypassCalciumCardiovascular DiseasesCarotid StenosisCell AgingCell Culture TechniquesCellsCephalicCerebrovascular CirculationCerebrovascular DisordersCerebrovascular systemCerebrumChronicDataDementiaDevelopmentDiseaseDoseEndothelial CellsEndotheliumExperimental ModelsExposure toFunctional disorderGeneticHealthHistologicHumanImpaired cognitionImpairmentIon ChannelIon Channel GatingLaboratoriesLaser Speckle ImagingLinkMeasuresMediatingMembraneModelingMorphologyMusPathologicPeptidesPeripheralPharmacologyPiezo 1 ion channelPlayProceduresPublic HealthRecommendationRegulationResearchRoleSignal TransductionStretchingStrokeSystemic blood pressureTestingTissuesTransgenic MiceVascular DiseasesVasodilationagedamyloid pathologybehavior testblood flow measurementbrain endothelial cellcardiovascular healthcerebrovascularcognitive developmentfield studyfunctional losshypoperfusionin vivomonomernotch proteinnovel therapeutic interventionpreventprogramsresilienceresponsesenescencesymposiumtranscriptomevascular cognitive impairment and dementia
项目摘要
Cerebrovascular dysfunction is a contributing factor to the development of cognitive impairment and dementia
in both Alzheimer’s disease (AD) and in non-AD pathologies. Vascular contributions to cognitive impairment and
dementia (VCID) is an evolving field of study which covers the overlap and interrelationship between vascular
disorders and disorders leading to dementia. More basic science research investigating the impact of aging, AD
pathology, and cerebrovascular function is currently needed.
Piezo1 is a recently identified mechanosensitive ion channel that gates calcium influx in response to membrane
stretch or increased shear forces. It is expressed in multiple tissues, but plays a critical role in cardiovascular health
and disease. In the peripheral vasculature, activation of this ion channel by luminal shear or by a selective agonist
promotes increased endothelial intracellular calcium and vasodilation. Our significant preliminary data provide
the first demonstration that endothelial Piezo1 plays an important role in regulating cerebral blood flow (CBF) and
contributes to microvascular stability. We also demonstrate that CBF can be enhanced by delivery of a selective
Piezo1 agonist (Yoda1) at doses that do not alter systemic blood pressure.
An intriguing recent study showed that shear-mediated Ca2+ influx in cells exogenously expressing human PIEZO1
was potently inhibited by amyloid beta (Ab) monomers (Ab40>Ab42). If these findings are similarly valid with
endogenously-expressed Piezo1 within the cerebral vasculature, it would suggest a new mechanism by which
elevated Ab contributes to impaired CBF regulation and the eventual development of VCID. We tested this
possibility with mouse brain microvascular endothelial cells (BMVECs). We found that exposure to human Ab40
indeed abolished the flow-mediated Ca2+ response, but that responsiveness to direct pharmacological Piezo1
activation remained intact. We further demonstrated that the in vivo CBF response to Yoda1 was also intact in
TgSwDI mice which express elevated levels of soluble Ab40 and Ab42. These provocative findings suggest that
while flow/shear-dependent function of cerebral endothelium may indeed be impaired by elevated Ab peptides,
this dysfunction may be “bypassed” by direct pharmacological activation of Piezo1.
In this proposal, we will test the overall hypothesis that loss of endothelial Piezo1 function (such as in conditions
of chronically reduced flow or elevated soluble Ab) leads to cerebrovascular dysregulation and the development
of VCID. In addition, we seek to establish proof-of-concept for a strategy to provide resilience to VCID by
pharmacologically “mimicking” flow-mediated endothelial activation with selective Piezo1 agonists.
Completion of these studies will establish a vital role of EC Piezo1 in the regulation of cerebral blood flow and
the pathological consequences of its functional loss in the development of VCID. These studies will further
establish the scientific justification for new therapeutic strategies aimed at restoring endothelial Piezo1 function
in the context of amyloid pathology.
脑血管功能障碍是认知障碍和痴呆症发展的一个促成因素
在阿尔茨海默病(AD)和非AD病理中。血管对认知障碍的贡献和
痴呆症(VCID)是一个不断发展的研究领域,它涵盖了血管之间的重叠和相互关系
失调症和失调症导致痴呆。更多基础科学研究调查老龄化的影响
病理学,脑血管功能是目前所需要的。
PIEZO1是新近发现的一种机械敏感离子通道,它能通过膜调节钙离子的内流
拉伸或增加剪切力。它在多种组织中表达,但在心血管健康中起着关键作用
和疾病。在外周血管系统中,通过管腔切变或选择性激动剂激活该离子通道
促进内皮细胞内钙的增加和血管扩张。我们重要的初步数据提供了
首次证明内皮Piezo1在调节脑血流(CBF)和脑血流(CBF)中发挥重要作用
有助于微血管的稳定。我们还证明,CBF可以通过提供选择性的
PIEZO1激动剂(Yoda1),剂量不改变全身血压。
最近一项耐人寻味的研究表明,剪切介导的钙离子内流外源表达人PIEZO1的细胞
被淀粉样β(Ab)单体(Ab40和GT;AB42)有效抑制。如果这些发现同样适用于
在脑血管中内源性表达Piezo1,这将提示一种新的机制,通过
抗体升高导致CBF调节受损,最终导致VCID的发生。我们测试了这个
与小鼠脑微血管内皮细胞(BMVECs)的可能性。我们发现接触人类AB40病毒
确实取消了流介导的钙反应,但这种对直接药理学Piezo1的反应
激活状态保持不变。我们进一步证明,体内对Yoda1的CBF反应也是完整的
TgSwDI小鼠,表达升高的可溶性Ab40和AB42水平。这些具有挑衅性的发现表明
虽然脑内皮细胞的血流/剪切依赖功能确实可能受到升高的抗体多肽的损害,
这种功能障碍可以通过Piezo1的直接药理激活而被“绕过”。
在这项提议中,我们将检验内皮Piezo1功能丧失(如在条件下)的总体假设
慢性血流量减少或可溶性抗体升高)导致脑血管调节失调和发展
是VCID的。此外,我们寻求为战略建立概念验证,通过以下方式提供对VCID的弹性
用选择性的Piezo1激动剂在药理学上“模仿”血流介导的内皮激活。
这些研究的完成将确立EC Piezo1在调节脑血流和
在VCID的发展过程中其功能丧失的病理后果。这些研究将进一步
建立旨在恢复内皮Piezo1功能的新治疗策略的科学合理性
在淀粉样蛋白病理的背景下。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Measurement of Uninterrupted Cerebral Blood Flow by Laser Speckle Contrast Imaging (LSCI) During the Mouse Middle Cerebral Artery Occlusion Model by an Inverted LSCI Setup.
- DOI:10.1007/978-1-0716-2926-0_9
- 发表时间:2023-01-01
- 期刊:
- 影响因子:0
- 作者:Hong, Sung-Ha;Doan, Andrea;Marrelli, Sean P
- 通讯作者:Marrelli, Sean P
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sean P Marrelli其他文献
Sean P Marrelli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sean P Marrelli', 18)}}的其他基金
Modifying endothelial Piezo 1 function to improve brain perfusion in AD/ADRD
修改内皮 Piezo 1 功能以改善 AD/ADRD 患者的脑灌注
- 批准号:
10658645 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
Targeting intramural von Willebrand factor (VWF) to improve vasomotor function, enhance brain parenchymal clearance, & delay development of cerebral amyloid angiopathy (CAA) in conditions of amyloid
针对壁内血管性血友病因子 (VWF) 改善血管舒缩功能,增强脑实质清除,
- 批准号:
10901009 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
SkyScan 1276: Multiscale Micro-CT SystemLaboratory
SkyScan 1276:多尺度微型 CT 系统实验室
- 批准号:
10177395 - 财政年份:2021
- 资助金额:
$ 62.02万 - 项目类别:
G-quadruplex DNA in senescence of the neurovascular unit
神经血管单元衰老中的 G-四链体 DNA
- 批准号:
10044252 - 财政年份:2020
- 资助金额:
$ 62.02万 - 项目类别:
Multiple mechanisms of TRPV1-mediated brain protection following stroke
TRPV1介导的中风后脑保护的多种机制
- 批准号:
9236509 - 财政年份:2017
- 资助金额:
$ 62.02万 - 项目类别:
Multiple mechanisms of TRPV1-mediated brain protection following stroke
TRPV1介导的中风后脑保护的多种机制
- 批准号:
9551722 - 财政年份:2017
- 资助金额:
$ 62.02万 - 项目类别:
TRPV1-mediated induction of a protective heat shock response after stroke
TRPV1 介导的中风后保护性热休克反应的诱导
- 批准号:
8807397 - 财政年份:2014
- 资助金额:
$ 62.02万 - 项目类别:
TRPV1-mediated induction of a protective heat shock response after stroke
TRPV1 介导的中风后保护性热休克反应的诱导
- 批准号:
8919475 - 财政年份:2014
- 资助金额:
$ 62.02万 - 项目类别:
Targeting thermoreceptors for therapeutic hypothermia
靶向温度感受器进行低温治疗
- 批准号:
8327106 - 财政年份:2011
- 资助金额:
$ 62.02万 - 项目类别:
Targeting thermoreceptors for therapeutic hypothermia
靶向温度感受器进行低温治疗
- 批准号:
8233629 - 财政年份:2011
- 资助金额:
$ 62.02万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 62.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 62.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 62.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)